转移性乳腺癌曲妥珠单抗联合化疗的最佳选择是什么？
What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?
机构信息
Institut du Cancer de l'Ouest Centre René Gauducheau, Bd Jacques Monod, 44805 Saint-Herblain, France.
出版信息
Expert Rev Anticancer Ther. 2012 Feb;12(2):195-201. doi: 10.1586/era.11.167.
PMID:22316367
Abstract
The HER2 gene and its role in pathogenicity in human breast cancer were detected in the 1980s. Trastuzumab is a monoclonal antibody directed against the HER2 membrane receptor. The aim of this article is to describe chemotherapy-trastuzumab combinations that have been evaluated in patients with HER2-positive metastatic breast cancer, and to define the possible standards and options.
摘要
HER2 基因及其在人类乳腺癌发病机制中的作用于 20 世纪 80 年代被发现。曲妥珠单抗是一种针对 HER2 膜受体的单克隆抗体。本文旨在描述已在 HER2 阳性转移性乳腺癌患者中评估的化疗联合曲妥珠单抗方案，并确定可能的标准和选择。
Zotero 插件